Pulmonary Hypertension

Pulmonary Hypertension Fund Opens at the HealthWell Foundation - PRNewswire Pulmonary Hypertension Fund Opens at the HealthWell Foundation - PRNewswire Posted: 11 Jan 2021 06:26 AM PST GERMANTOWN, Md. , Jan. 11, 2021 /PRNewswire/ -- The HealthWell Foundation ® , an independent non-profit that provides a financial lifeline for inadequately insured Americans, is excited to announce that it has launched a new fund to assist individuals living with pulmonary hypertension (PH). Through the fund, HealthWell will provide up to $10,000 in medication copayment or insurance premium assistance for a 12-month grant period to eligible Medicare patients who have annual household incomes up to 500 percent of the federal poverty level. About Pulmonary Hypertension Pulmonary Hypertension is a term used to describe high blood pressure in the lungs from any cause. PH is a condition that affects the blood vessels in the lungs, causing vessels to become stiff,...

PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation - Science PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation - Science New Hope Against Diseases Marked by Progressive Scarring of Lung Tissue - HealthDay News Tracleer for Digital Ulcers Lowers PH Risk in Scleroderma, Study Finds - Scleroderma News Prevalence, Incidence of PAH in SSc Steady Over Time, Report Says - AJMC.com Managed Markets Network PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation - Science Posted: 26 Jan 2021 11:14 AM PST Not a PERK for pulmonary arterial hypertension The vascular remodeling that occurs in pulmonary arterial hypertension (PAH) is eventually fatal because it leads to right ventricular heart failure. PAH induces the unfolded protein response (UPR), and Shimizu et ...

Optimism for Interstitial Lung Disease–Associated Pulmonary Hypertension? - nejm.org Optimism for Interstitial Lung Disease–Associated Pulmonary Hypertension? - nejm.org Inhaled Treprostinil Shows Promise for ILD-Induced Pulmonary Hypertension - MD Magazine Registry highlights 'evolving characteristics' of patients with PAH - Healio COVID Vaccine for Patient With Rare Disease? Best Guess Is Yes - MedPage Today Optimism for Interstitial Lung Disease–Associated Pulmonary Hypertension? - nejm.org Posted: 13 Jan 2021 12:00 AM PST Pulmonary hypertension scares us, and for good reason. Pulmonary hypertension may be caused by an intrinsic pulmonary vasculopathy — termed pulmonary arterial hypertension — or it may complicate other, more common problems such as interstitial lung disease, in which it signals the presence of advanced, often end-stage disease. 1 Regardless of its cause, witho...

COVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA... - Pulmonary Hypertension News COVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA... - Pulmonary Hypertension News Posted: 28 Jan 2021 10:15 AM PST The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected to pose little risk to the rare disease community, including to patients with compromised immune systems or those participating in gene therapy studies. That was the message of a recent webinar, hosted by the National Organization for Rare Disorders (NORD), in which officials from the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) addressed concerns from the rare disease community regarding the newly available COVID-19 vaccines. The webinar was sponsored by the ALS Association , the Cystic Fibrosis Foundation, and t...

Recent updates in pulmonary hypertension: New treatment options, inhaled therapy and more - Healio Recent updates in pulmonary hypertension: New treatment options, inhaled therapy and more - Healio Posted: 19 Aug 2020 12:00 AM PDT August 19, 2020 2 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio The Healio editors have compiled a list of recent updates in the management and treatment of pulmonary hypertension. Recent news includes an update from the TRITON study on initial triple oral therapy compared with double therapy in newly diagnosed PAH; new data on inhaled t...

[Full text] Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and | COPD - Dove Medical Press [Full text] Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and | COPD - Dove Medical Press Posted: 27 Jan 2021 11:29 AM PST Introduction Respiratory physicians are aware of a relatively new interstitial syndrome which is linked to heavy current or former smoking called Combined Pulmonary Fibrosis and Emphysema (CPFE). The disease was first described by Cottin in 2005. It has since been increasingly recognized as a separate clinical entity and is characterized by progressive worsening of respiratory symptoms, decline of lung function and a high mortality. Currently, no specific drug treatment is available, so treatment focuses on both the emphysema component and the fibrosis component. Major symptoms include dyspnea on exertion (functional class III or IV of the New York Heart Association) 1 in almost all patie...